Therapy of aggressive pituitary tumors

Bibliography

• Kaltsas GA, Grossman AB. Malignant pituitary tumors. Pituitary 1998;1:69-81
   PubMedGoogle Scholar
• Scheithauer BW, Gaffey TA, Lloyd RV, Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 2006;59:341-53
   PubMed Web of Science ®Google Scholar
• Selman WR, Laws ER, Scheithauer BW, The occurrence of dural invasion in pituitary adenomas. J Neurosurg 1986;64:402-7
   PubMed Web of Science ®Google Scholar
• Hornyak M, Couldwell WT. Multimodality treatment for invasive pituitary adenomas. Postgrad Med 2009;121(2):168-76
   PubMedGoogle Scholar
• Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 2009;12(3):256-60
   PubMedGoogle Scholar
• Kaltsas GA, Panagiotis N, Kontogeorgos G, Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089-99
   PubMed Web of Science ®Google Scholar
• Lopes MB, Scheithauer BW, Schiff D. Pituitary carcinoma: diagnosis and treatment. Endocrine 2005;28:115-21
   PubMedGoogle Scholar
• Gurlek A, Karavitaki N, Ansorge O, Wass JA. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 2007;156:143-53
   PubMedGoogle Scholar
• Zada G, Woodmansee WW, Ramkissoon S, Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 2011;114(2):336-44
   PubMedGoogle Scholar
• Lloyd RJ, Kovacs K, Young WF Jr, Tumours of the pituitary gland. Pathology and Genetics. In: DeLellis RA, Lloyd RV, Heitz PU, editors, Tumours of Endocrine Tumours. International Agency for Research and Cancer (IARC), Lyon; 2004. p. 9-48
   Google Scholar
• Saeger W, Ludecke DK, Buchfelder M, Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J of Endocrinol 2007;156:203-16
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Mukherjee JJ, Plowman PN, The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumours. J Clin Endocrinol Metab 1998;83:4233-8
   PubMed Web of Science ®Google Scholar
• Meij BP, Lopes MB, Ellegala DB, The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 2002;96:195-208
   PubMed Web of Science ®Google Scholar
• Greenman Y, Woolf P, Coniglio J, Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastases detected by 111-indium pentetreotide scan. J Clin Endocrinol Metab 1996;81:1628-33
   PubMedGoogle Scholar
• Vaquero J, Herrero J, Cincu R. Late development of frontal prolactinoma after resection of pituitary tumor. J Neurooncol 2003;64:255-8
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, Lombardi G, Novel insights in dopamine receptor physiology. Eur J Endocrinol 2007;156(Suppl):13-21
   PubMedGoogle Scholar
• Gillam MP, Molitch ME, Lombardi G, Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534
   PubMed Web of Science ®Google Scholar
• Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007;156(2):225-31
   PubMedGoogle Scholar
• Popovic EA, Vattuone JR, Siu KH, Malignant prolactinomas. Neurosurgery 1991;29:127-30
   PubMedGoogle Scholar
• Thapar K, Kovacs K, Muller P. Clinical-pathologic correlations of pituitary tumors. Baillieres Clin Endocrinol Metab 1995;9:243-70
   PubMedGoogle Scholar
• Walker JD, Grossman AB, Anderson JV, Malignant prolactinoma with extracanial metastases: a report of three cases. Clin Endocrinol 1993;38:411-19
   PubMed Web of Science ®Google Scholar
• Hurel SJ, Harris PE, McNicol AM, Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997;82:2962-5
   PubMedGoogle Scholar
• Colao A, Pivonello R, Auriemma RS, Predictors of tumor shrinkage after primari therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006;91(6):2112-18
   PubMedGoogle Scholar
• Petrossians P, Borges-Martin L, Espinoza C, Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-6
   PubMed Web of Science ®Google Scholar
• Cozzi R, Montini M, Attanasio R, Primary treatment of acromegaly with octreotide LAR: long-term (up to nine years) prospective study af its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403
   PubMed Web of Science ®Google Scholar
• Murray RD, Kim K, Ren SG, The novel somatostatin ligand (SOM 230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 2004;89(6):3027-32
   PubMed Web of Science ®Google Scholar
• van der Hoek J, de Herder WW, Feelders RA, A single-dose comparison of the acute effects between the new somatostatin analog SOM 230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-45
   PubMed Web of Science ®Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008;286(1-2):69-74
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, Pasireotide (SOM230) demonstrates efficacy and safety in patients with Acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010;95(6):2781-9
   PubMedGoogle Scholar
• Boscaro M, Ludlam WH, Atkinson B, Treatment of pituitary dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;94:115-22
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, Feelders R, The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J of Endocrinol 2005;152:645-54
   PubMed Web of Science ®Google Scholar
• Feelders RA, de Bruin C, Pereira AM, Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease. N Engl J Med 2010;362:19
   Google Scholar
• Drake WM, Parkinson C, Besser GM, Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol Metab 2001;12:408-13
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, Treatment of acromegaly with the growth hormone-receptor anatgonist pegvisomant. N Engl J Med 2000;342:1171-7
   PubMed Web of Science ®Google Scholar
• Buchfelder M, Schlaffer S, Droste M, The German ACROSTUDY: past and present. Eur J Endocrinol 2009;161(Suppl 1):S3-S10
   Google Scholar
• Gruszka A, Ren SG, Dong J, Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007;148(12):6107-14
   PubMedGoogle Scholar
• Saveanu A, Gunz G, Guillen S, Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006;83(3-4):258-63
   PubMedGoogle Scholar
• Florio T, Barbieri F, Spaziante R, Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 2008;15(2):583-96
   PubMed Web of Science ®Google Scholar
• Peverelli E, Olgiati L, Locatelli M, The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett 2010;288(2):170-6
   PubMedGoogle Scholar
• Prasad D. Clinical results of conformal radiotherapy and radiosurgery for pituitary adenoma. Neurosurg Clin N Am 2006;17:129-41
   PubMedGoogle Scholar
• Brada M, Rajan B, Traish D, The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) 1993;38:571-8
   PubMed Web of Science ®Google Scholar
• Imboden PNE, Borruat FX, De Tribolet N, Non-functioning pituitary carcinoma. Pituitary 2004;7:149-56
   PubMedGoogle Scholar
• Martin NA, Hales M, Wilson CB. Cerebellar metastases from a prolactinoma during treatment with bromocriptine. J Neurosurg 1981;55:615-19
   PubMedGoogle Scholar
• Epstein A, Epstein BS, Molho L, Carcinoma of the pituitary gland with metastases to the spinal cord and roots of the cauda equina. J Neurosurg 1964;21:846-53
   PubMedGoogle Scholar
• Cartwright DM, Miller TR, Nasr AJ. Fine needl aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: a report of two cases and review of the literature. Diagn Cytopathol 1994;11:68-73
   PubMed Web of Science ®Google Scholar
• Walker JD, Grossman A, Anderson JV, Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol (Oxf) 1993;38(4):411-19
   PubMedGoogle Scholar
• Minniti G, Traish D, Ashley S, Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 2005;90:800-4
   PubMed Web of Science ®Google Scholar
• Brada M, Ford D, Ashley S, Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma. Br Med J 1992;304:1343-6
   PubMed Web of Science ®Google Scholar
• Evans DGR, Birch JM, Ramsden RT, Malignant transformation and new primary tumors after therapeutic radiation for benign disease: substantial risks in certain tumor prone syndromes. J Med Genet 2006;43:289-94
   PubMed Web of Science ®Google Scholar
• Swords FM, Allan CA, Plowman PN, Stereotactic radiosurgery. XVI. A treatment for previously irradiated pituitary adenomas. J Clin Endocrinol Metab 2003;88:5334-40
   PubMed Web of Science ®Google Scholar
• Castro DG, Cecilio SAJ, Canteras MM. Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety. Radiat Oncol 2010;5:109
   PubMedGoogle Scholar
• Rowland NC, Aghi MK. Radiation treatment strategies for acromegaly. Neurosurg Focus 2010;29(4):E12
   Google Scholar
• Castinetti F, Nagai M, Morange I, Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 2009;94:3400-7
   PubMed Web of Science ®Google Scholar
• Castinetti F, Regis J, Dufour H, Brue T. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 2010;6:214-23
   PubMed Web of Science ®Google Scholar
• Choi JY, Chang JH, Chang JW, Radiological and hormonal responses of functioning pituitary adenomas after gamma knife radiosurgery. Yonsei Med J 2003;44:602-7
   PubMed Web of Science ®Google Scholar
• Hockaday TD, Laing AH, Welbourn RB, Hartog M. Letter: proton beam therapy for acromegaly. BMJ 1975;1:457
   PubMedGoogle Scholar
• Kjellberg RN, Kliman B. Bragg peak proton treatment for pituitary-related conditions. Proc R Soc Med 1974;67:32-3
   PubMedGoogle Scholar
• Sheehan JP, Niranjan A, Sheehan JM, Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005;102:678-91, 28
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med 1995;25:272-8
   PubMedGoogle Scholar
• Kaltsas G, Rockall A, Papadogias D, Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors. Eur J Endocrinol 2004;151:15-27
   PubMedGoogle Scholar
• Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 1998;10:58-65
   PubMedGoogle Scholar
• Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000;62:92-7
   PubMed Web of Science ®Google Scholar
• Hofland LJ, de Herder WW, Waaijers M, Interferon-alfa-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. J Clin Endocrinol Metab 1999;84:3336-43
   PubMedGoogle Scholar
• Kaltsas GA, Mukherjee JJ, Plowman PN, The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 1998;83:4233-8
   PubMed Web of Science ®Google Scholar
• Labeur M, Refojo D, Wolfel B, Interferon-g inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases–signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway. J of Endocrinol 2008;199:177-89
   PubMedGoogle Scholar
• Vaughan NJA, Laroche CM, Goodman I, Pituitary Cushing's disease arising from a previously non-functional corticotrophic chromophobe adenoma. Clin Endocrinol (Oxf) 1985;22:147-53
   PubMedGoogle Scholar
• Kasperlik-Zaluska AA, Wislawski J, Kaniewska J, Cytostatics for acromegaly: marked improvement in a patient with an invasive pituitary tumour. Acta Endocrinol (Copenh) 1987;116:347-9
   PubMedGoogle Scholar
• Kaizer FE, Orth DN, Mukai K, A pituitary parasellar tumour with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides. J Clin Endocrinol Metab 1983;57:649-53
   PubMedGoogle Scholar
• Peterson T, McFarlane IA, McKenzie JM, Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psychol 1992;55:1205-6
   PubMedGoogle Scholar
• Mixson AJ, Friedman TC, Katz DA, Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 1993;76:529-33
   PubMedGoogle Scholar
• Assai A, Matsutani M, Nobuaki F, Malignant growth hormone-secreting pituitary adenoma with haematogenous dural metastasis: case report. Neurosurgery 1988;22:1091-4
   PubMedGoogle Scholar
• Gollard R, Kosty M, Cheney C, Prolactin secreting pituitary carcinoma with implants in the cheek pouch and metastases to the ovaries. Cancer 1995;76:1814-20
   PubMed Web of Science ®Google Scholar
• Fadul CE, Kominsky AL, Meyer LP, Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006;105:621-6
   PubMed Web of Science ®Google Scholar
• Lim S, Shahinian H, MMaya MM, Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006;7:518-20
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shahinian H, Hakimian B, Temodar: novel treatment for pituitary carcinoma. US Endocr Soc 2004;138:43-5
   Google Scholar
• Kovacs K, Horvath E, Syro LV, Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 2007;38:185-9
   PubMed Web of Science ®Google Scholar
• Syro LV, Uribe H, Penagos LC, Antitumor effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol 2006;65:549-53
   Google Scholar
• Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-51
   PubMedGoogle Scholar
• Stupp R, Gander M, Leyvraz S, Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol 2001;2:552-60
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S, Clinical trial substantiates the predictive value of 0-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4
   PubMed Web of Science ®Google Scholar
• Losa M, Mazza E, Terreni MR, Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J of Endocrinol 2010;163(6):843-51
   PubMed Web of Science ®Google Scholar
• Bode H, Seiz M, Lammert A, SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases. Exp Clin Endocrinol Diabetes 2010;118(10):760-3
   PubMedGoogle Scholar
• Morin E, Berthelet F, Weisnagel J, Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 2010. [Epub ahead of print]
   Google Scholar
• Syro LV, Ortiz LD, Scheithauer BW, Treatment of pituitary neoplasms with temozolomide. Cancer 2010;117(3):454-62
   PubMedGoogle Scholar
• Levin N, Lavon I, Zelikovitsh B, Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006;106:1759-65
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Godard S, Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4
   PubMed Web of Science ®Google Scholar
• Takeshita A, Inoshita N, Taguchi M, High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol 2009;161(4):553-9
   PubMedGoogle Scholar
• Kovacs K, Scheithauer BW, Lombardero M, MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 2008;115(2):261-2
   PubMedGoogle Scholar
• McCormack AI, McDonald KL, Gill AJ, Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009;71(2):226-33
   PubMedGoogle Scholar
• Raverot G, Sturm N, de Fraipont F, Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a french multicenter experience. J Clin Endocrinol Metab 2010;95(10):4592-9
   PubMed Web of Science ®Google Scholar
• Bush ZM, Longtine JA, Cunningham T, Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression. J Clin Endocrinol Metab 2010;95(11):E280-90
   PubMedGoogle Scholar